Payment overview · 2025
General Payments
$1,517.37
76 reported records · 24 companies
Healthcare provider profile · identity verified
Esther Cahn
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · BALTIMORE, MD · NPI 1023893815
Verified facts
What the public records show
CMS Open Payments records show Esther Cahn received $1,517.37 in general payments during 2025 across 76 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $231.25 | 15.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.00 | 12.0% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.33 | 11.8% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $113.40 | 7.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $100.02 | 6.6% | 5 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $99.00 | 6.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.91 | 4.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.76 | 3.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $53.06 | 3.5% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $46.86 | 3.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.98 | 3.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.21 | 2.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.05 | 2.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $41.08 | 2.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $31.04 | 2.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $29.38 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.19 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.35 | 1.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.30 | 1.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.18 | 1.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.87 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.68 | 1.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.47 | 1.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.00 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,418.37 | 75 |
| Education | $99.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $231.25 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.00 | 20 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $145.98 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $119.67 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $113.40 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $100.02 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.76 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $53.06 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.23 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $46.86 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.97 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $35.52 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $29.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.82 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.82 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.16 | 4 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 22 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 282 | 120 |
| Ramipril | Ramipril | 225 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 207 | 83 |
| Ezetimibe | Ezetimibe | 182 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 49 |
| Chlorthalidone | Chlorthalidone | 98 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 36 |
| Lisinopril | Lisinopril | 69 | 29 |
| Omeprazole | Omeprazole | 63 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 31 |
| Metformin Hcl | Metformin Hcl | 56 | 21 |
| Losartan Potassium | Losartan Potassium | 52 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 17 |
| Sertraline Hcl | Sertraline Hcl | 48 | 21 |
| Jardiance | Empagliflozin | 46 | 22 |
| Synthroid | Levothyroxine Sodium | 43 | 15 |
| Ozempic | Semaglutide | 41 | 12 |
| Montelukast Sodium | Montelukast Sodium | 40 | 15 |
| Trulicity | Dulaglutide | 40 | 11 |
| Allopurinol | Allopurinol | 39 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 25 |
| Metformin Hcl Er | Metformin Hcl | 37 | 18 |
| Eliquis | Apixaban | 34 | suppressed |
| Valsartan | Valsartan | 33 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Gabapentin | Gabapentin | 28 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | 12 |
| Celecoxib | Celecoxib | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | 11 |
| Glimepiride | Glimepiride | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Famciclovir | Famciclovir | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,517.37 · 76 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, CLOSUREFAST, Cologuard Collection Kit, ENFLONSIA, FABRAZYME, GVOKE HYPOPEN, JARDIANCE, JOURNAVX, KRYSTEXXA, Kerendia, Korlym, Leqembi, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, Senza, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error